Dr. Larry Ereshefsky to Present at BioXcel’s Virtual KOL Event to Highlight BXCL501 as a Potential Treatment for Agitation
BioXcel Therapeutics, a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, will host a virtual Key Opinion Leader (“KOL”) event on Friday, February 19, 2021 from 11:00 am to 2:00 pm ET. The event aims to highlight BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine (“Dex”), and its potential as a treatment option for multiple neuropsychiatric conditions. Apex Innovative Sciences‘ Chief Scientific Officer, Larry Ereshefsky, Pharm.D., will present on BXCL501’s potential to treat dementia-related agitation. A live webcast of the event will be accessible through the Investors section of the Company’s website at www.bioxceltherapeutics.com on February 19 at 11:00 am ET. Following the event, the webcast will be archived on the Company’s website for at least 30 days.